Key points:
·New Law Implemented: Starting from August 3, 2023, Russia will impose criminal penalties on unmarked nicotine-containing products (including e-liquids).
·Penalties: Manufacturers and sellers who violate labeling regulations may face fines of up to 500,000 rubles (approximately $5,000), forced labor, up to three years in prison, and an additional fine of 120,000 rubles (approximately $1,200).
·Scale of Violation: Unmarked products with a circulation amount exceeding 100,000 rubles (approximately $1,000) are considered large-scale violations, while those exceeding 1 million rubles (approximately $10,000) are classified as particularly large-scale violations.
·Health Risks: Experts point out that using e-cigarettes may lead to allergic reactions, manifested as itching, swelling, rashes, etc.
【2Firsts News Flash】According to a report on August 3, Russia has implemented a new law that imposes criminal penalties on the circulation of unmarked nicotine products (including e-liquid) starting from August 3. This means that not only unmarked tobacco products, but also all unmarked nicotine products will be subject to legal sanctions.
According to the legal text, manufacturers and sellers who violate labeling regulations may be fined up to a maximum of 500,000 rubles (approximately $5,000). In addition, alternative penalties such as forced labor or imprisonment for up to three years, as well as an additional fine of up to 120,000 rubles (approximately $1,200), are also specified.
According to the law, the distribution of unmarked products exceeding 100,000 rubles (approximately $1,000) is considered a large-scale violation. When the amount exceeds 1 million rubles (approximately $10,000), it is classified as a particularly large-scale violation.
Earlier, immunologist Tatiana Ustinova had mentioned that the use of e-cigarettes may lead to allergic reactions. This is due to the toxic substances found in e-liquid and produced during heating. According to her information, allergies to e-cigarettes typically manifest as itching, eyelid swelling, rash, and other symptoms.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
